Childhood cancers trials in Netherlands

In Netherlands 119 Also abroad 2459

119 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 4Taking people
Dabrafenib and/or Trametinib Rollover Study
Where
Utrecht
Age
18 years to 100 years
People
100 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT03340506 · EU 2023-509318-13-00
Phase 2Taking people
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Where
Utrecht
Age
12 years and over
People
355 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT04924075 · EU 2023-504853-11-00
Phase 2Taking people
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
Where
Utrecht
Age
1 year to 18 years
People
50 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07354074
Phase 2/3Taking people
A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
Where
Amsterdam, Nieuwegein, Nijmegen, Rotterdam, Utrecht
Age
12 years and over
People
340 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07570173 · EU 2025-522267-15-00
Phase 2Taking people
177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma
Where
Utrecht
Age
18 months to 64 years
People
24 worldwide
Run by
Jakob Stenman
See details and how to joinNCT04903899 · EU 2023-503684-42-00
Phase 1/2Taking people
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Where
Amsterdam, Groningen
Age
12 years and over
People
840 worldwide
Run by
Nuvalent Inc.
See details and how to joinNCT05384626 · EU 2024-514266-39-00
Phase 3Taking people
A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
Where
Utrecht
Age
1 year to 64 years
People
130 worldwide
Run by
Memorial Sloan Kettering Cancer Center
See details and how to joinNCT07223021 · EU 2025-523096-34-00
Phase 2/3Taking people
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Where
Amsterdam, Maastricht, Nijmegen, Rotterdam, Utrecht
People
1,541 worldwide
Run by
Celgene
See details and how to joinNCT03435796 · EU 2023-504201-36-00
Phase 1/2Taking people
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Where
Utrecht
Age
6 months to 25 years
People
90 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06395103 · EU 2023-507178-41-00
Phase 1/2Taking people
A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)
Where
Utrecht
Age
1 month to 17 years
People
134 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07630974 · EU 2025-522339-32-00
No phaseTaking people
Met Non Small Cell Cancer Registry (MOMENT)
Where
Amsterdam, Groningen, Leiden, Roosendaal, Rotterdam
People
700 worldwide
Run by
EMD Serono Research & Development Institute, Inc.
See details and how to joinNCT05376891
No phaseTaking people
"Less-is-more in Barrett-surveillance" Care Evaluation of Barrett's Patients With Low-Risk in Whom Endoscopic Surveillance is Stopped. The BLISS Project.
Where
Amsterdam
People
3,156
Run by
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
See details and how to joinNCT06803147
Phase 1Taking people
Study of Lunresertib Alone or in Combination With RP-3500 or Zedoresertib (Debio 0123) in Patients With Advanced Solid Tumors
Where
Groningen
Age
12 years and over
People
464 worldwide
Run by
Debiopharm International SA
See details and how to joinNCT04855656 · EU 2023-510063-35-00
Phase 3Taking people
International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)
Where
Utrecht
Age
1 year to 64 years
People
750 worldwide
Run by
Charite University, Berlin, Germany
See details and how to joinNCT07476729 · EU 2023-509392-17-00
Phase 3Taking people
Fight Osteosarcoma Through European Research Evolving Study Platform From Diagnosis to Relapse
Where
Groningen, Leiden, Nijmegen, Utrecht
Age
4 years and over
People
530 worldwide
Run by
Gustave Roussy, Cancer Campus, Grand Paris
See details and how to joinNCT07871864
Phase 3Taking people
International study for children and adolescents with standard risk ALK-positive anaplastic large cell lymphoma (ALCL) estimating the efficacy of Vinblastine
Where
Utrecht
Age
Up to 17 years
People
137 worldwide
Run by
GPOH gGmbH
See details and how to join2022-501454-11-00 · EU 2022-501454-11-00
Phase 2Taking people
INTERACT Stomach-II
Where
Amsterdam, Eindhoven, Rotterdam
People
55
Run by
Erasmus Medical Center
See details and how to joinNCT07133490 · EU 2025-521468-36-00
Phase 3Not yet taking people in Netherlands
Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma
Where
Utrecht
Age
Up to 5 years
People
96 worldwide
Run by
Nationwide Children's Hospital
See details and how to joinNCT07291102 · EU 2024-517133-40-00
Phase 3Taking people
Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia
Where
Utrecht
Age
1 day to 1 year
People
160 worldwide
Run by
Princess Maxima Center for Pediatric Oncology
See details and how to joinNCT05327894 · EU 2022-502503-30-00
Phase 3Taking people
Teicoplanin as Infection Prophylaxis in Pediatric Acute Myeloid Leukemia (Pro-Teico study)
Where
Utrecht
Age
Up to 64 years
People
128 worldwide
Run by
Prinses Maxima Centrum voor Kinderoncologie B.V.
See details and how to join2023-506546-23-00 · EU 2023-506546-23-00
Phase 1/2Taking people
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
Where
Utrecht
Age
1 year to 17 years
People
70 worldwide
Run by
Incyte Biosciences International Sàrl
See details and how to joinNCT03934372 · EU 2023-509699-41-00
Phase 1/2Taking people
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Where
Utrecht
Age
30 days and over
People
447 worldwide
Run by
Syndax Pharmaceuticals
See details and how to joinNCT04065399 · EU 2024-513759-34-00
Phase 1Taking people
Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia
Where
Utrecht
Age
0 years to 21 years
People
20 worldwide
Run by
PedAL BCU, LLC
See details and how to joinNCT06376162 · EU 2023-505262-28-00
No phaseNot yet taking people in Netherlands
Off-line Adaptive Proton Therapy
Where
Groningen
Age
16 years and over
People
100
Run by
University Medical Center Groningen
See details and how to joinNCT07866547
Phase 1/2Not yet taking people in Netherlands
Study of the safety and efficacy of asciminib in pediatric and young adult participants with r/r Ph+ or ABL-class Ph-like ALL
Where
Utrecht
Age
Up to 64 years
People
22 worldwide
Run by
Novartis Pharma AG
See details and how to join2025-522019-40-00 · EU 2025-522019-40-00